Literature DB >> 3202221

Pylorectomy reduces the satiety action of cholecystokinin.

T H Moran1, L Shnayder, A M Hostetler, P R McHugh.   

Abstract

Rat gastric cholecystokinin (CCK) receptors are localized to the circular muscle layer of the pyloric sphincter, and a role for these receptors in the mediation of CCK satiety has been proposed. To directly assess the contribution of this receptor population in CCK satiety, the area of the pyloric sphincter containing these receptors was surgically removed, and the behavioral responses to CCK were compared pre- and postpylorectomy. The presence of CCK receptors in the gastroduodenal junction was assessed by either in vitro CCK receptor autoradiography or in vitro contractile response to CCK. The results depended on the time after pylorectomy during which testing occurred. Two to 3 wk after pylorectomy rats demonstrated a significant attenuation of CCK satiety such that while the response to 1 and 2 micrograms/kg was intact, any additional inhibition by 4 and 8 micrograms/kg was eliminated. At this time, no evidence of CCK receptors around the gastroduodenal junction was found. In contrast, 2-3 mo after pylorectomy, the normal dose-response inhibition to CCK was intact. Evidence for the presence of CCK binding sites at the gastroduodenal junction was found by both autoradiography and physiological assessment. These results indicate a role for pyloric CCK receptors in the mediation of CCK satiety.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3202221     DOI: 10.1152/ajpregu.1988.255.6.R1059

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

Review 1.  [Regulation of food intake].

Authors:  W Langhans; E Scharrer
Journal:  Z Ernahrungswiss       Date:  1990-06

Review 2.  Central control of body weight and appetite.

Authors:  Stephen C Woods; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

Review 3.  Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors.

Authors:  Timothy H Moran; Sheng Bi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 4.  New advances in models and strategies for developing anti-obesity drugs.

Authors:  Gilbert W Kim; Jieru E Lin; Erik S Blomain; Scott A Waldman
Journal:  Expert Opin Drug Discov       Date:  2013-04-29       Impact factor: 6.098

Review 5.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 6.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

7.  Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.

Authors:  Michael A Valentino; Francheska Colon-Gonzalez; Jieru E Lin; Scott A Waldman
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 8.  Obesity pharmacotherapy: what is next?

Authors:  Francheska Colon-Gonzalez; Gilbert W Kim; Jieru E Lin; Michael A Valentino; Scott A Waldman
Journal:  Mol Aspects Med       Date:  2012-10-24

Review 9.  Unraveling the obesity of OLETF rats.

Authors:  Timothy H Moran
Journal:  Physiol Behav       Date:  2007-11-29

10.  Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.

Authors:  Yan Yang; Alexander A Moghadam; Zachary A Cordner; Nu-Chu Liang; Timothy H Moran
Journal:  Endocrinology       Date:  2014-06-20       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.